FDA Approves Lilly and Incyte’s OLUMIANT (baricitinib) As First and Only Systemic Medicine for Adults with Severe Alopecia Areata
Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ:INCY) announced today that the U.S. Food and Drug Administration (FDA) has approved OLUMIANT® (baricitinib), a once-daily pill, as a first-in-disease systemic treatment…
